PDF(Pubmed)
Abstract：
Most of the complications and deaths related to seasonal flu occur in the elderly population (≥65 years) with comorbidities, and the influenza vaccine is the most effective way to prevent them. Immunization is less effective in older adults due to immunosenescence. MF59-adjuvanted vaccines, designed to improve the magnitude, persistence and amplitude of the immune response in elderly people, have been used in clinical practice since 1997 in their trivalent formulation and, since 2020, in their tetravalent formulation. Data from various studies show that these vaccines are not only safe for all age groups, with a reactogenicity profile similar to that of the conventional vaccine, but also that they are especially effective in boosting the immune response in the population aged 65 or over by increasing antibody titers after vaccination and significantly reducing the risk of hospital admission. Adjuvanted vaccines have been shown to provide cross-protection against heterologous strains and to be as effective as the high-dose vaccine in the population aged 65 or over. In this review, the scientific evidence on the efficacy and effectiveness of the MF59-adjuvanted vaccine in real clinical practice in people ≥65 years of age is analyzed through a narrative and descriptive review of the literature with data from clinical trials, observational studies and systematic reviews or meta-analysis.
摘要：
大多数与季节性流感相关的并发症和死亡发生在有合并症的老年人群（≥65岁）。流感疫苗是预防它们的最有效方法。由于免疫衰老，免疫在老年人中效果较差。MF59佐剂疫苗，旨在提高震级，老年人免疫反应的持续性和幅度，自1997年以来已在临床实践中使用其三价制剂，自2020年以来，在他们的四价配方中。各种研究的数据表明，这些疫苗不仅对所有年龄组都是安全的，具有与常规疫苗相似的反应原性特征，而且，它们通过增加疫苗接种后的抗体滴度并显着降低入院风险，特别有效地增强65岁或65岁以上人群的免疫反应。已显示,在65岁或以上的人群中,佐剂疫苗提供针对异源菌株的交叉保护,并且与高剂量疫苗一样有效。在这次审查中,通过对临床试验数据的文献进行叙述性和描述性回顾，分析了MF59佐剂疫苗在65岁以上人群实际临床实践中的功效和有效性的科学证据，观察性研究和系统评价或荟萃分析。
